Polyethylene oxide 150mg lozenges
Requires a prescription from a doctor or prescriber
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Yellow Card
Report side effects (MHRA)
Drug safety updates
MHRA alerts for Polyethylene oxide
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Polyethylene oxide
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0.
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 9 · 1959–2026
Showing the 50 most relevant studies, sorted by most relevant.
Toshio Yoshihara, Hiroyuki Tadokoro, Shunsuke Murahashi
The Journal of Chemical Physics, 1964
Neil P. Desai, Jeffrey A. Hubbell
Journal of Biomedical Materials Research, 1991
Josephine Y. T. Chong, Xavier Mulet, Lynne J. Waddington, et al.
Soft Matter, 2011
Wang C, Wen Z, Chen W, et al.
2025
Junoh H, Awang N, Zakria HS, et al.
2024
Polyethylene oxide (PEO) has become a highly sought-after polymer electrolyte for lithium-ion batteries (LIBs) due to its high ionic conductivity, strong mechanical properties, and broad electrochemical stability range. However, its usefulness is hindered by its limited ionic conductivity at typical temperatures (<60 °C). Many researchers have delved into the integration of active fillers into the PEO matrix to improve the ionic conductivity and overall efficiency of composite polymer electrolytes (CPEs) for LIBs. This review delves deeply into the latest developments and insights in CPEs for LIBs, focusing on the role of PEO-active filler composites. It explores the impact of different types and morphologies of active fillers on the electrochemical behavior of CPEs. Additionally, it explores the mechanisms that contribute to the improved ionic conductivity and Li-ion transport in PEO-based CPEs. This paper also emphasizes the present obstacles and prospects in the advancement of CPEs containing PEO-active filler composites for LIBs. It serves as a valuable reference for scientists and engineers engaged in the domain of advanced energy storage systems, offering insights for the forthcoming development and enhancement of CPEs to achieve superior performance in LIBs.
Abstract licence: CC BY
Shuntaro Uenuma, Di Liu, Kohzo Ito
2026
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Scientific data (pharmacology, interactions, ADME) is not yet available for this medicine. Clinical sections are sourced from the NHS dm+d database.